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As part  of  the  vaccination  activities  against  inﬂuenza  A[H1N1]pdm  vaccine  in  2009–2010,  countries  in
Latin  American  and  the  Caribbean  (LAC)  implemented  surveillance  of events  supposedly  attributable  to
vaccines  and immunization  (ESAVI).  We  describe  the serious  ESAVI  reported  in  LAC  in  order  to  further
document  the  safety  proﬁle  of this  vaccine  and  highlight  lessons  learned.
We  reviewed  data  from  serious  H1N1  ESAVI  cases  from  LAC  countries  reported  to  the  Pan  Amer-
ican  Health  Organization/World  Health  Organization.  We  estimated  serious  ESAVI  rates  by  age  and
target  group,  as  well  as  by  clinical  diagnosis,  and completed  descriptive  analyses  of  ﬁnal  outcomes  and
classiﬁcations  given  in  country.
A total  of  1000 serious  ESAVI  were  reported  by  18  of  the  29  LAC  countries  that  vaccinated  against
A[H1N1]pdm.  The  overall  reporting  rate in LAC  was  6.91  serious  ESAVI  per  million  doses,  with  country
reporting  rates  ranging  from  0.77  to 64.68  per  million  doses.  Rates  were  higher  among  pregnant  women
(16.25  per  million  doses)  when  compared  to health  care  workers  (13.54  per  million  doses)  and  individuals
with  chronic  disease  (4.03  per  million  doses).  The  top  three  most  frequent  diagnoses  were  febrile  seizures
(12.0%),  Guillain-Barré  Syndrome  (10.5%)  and  acute  pneumonia  (8.0%).  Almost  half  (49.1%) of the  serious
ESAVI  were  reported  among  children  aged  <18 years  of age;  within  this  group, the  highest  proportion
of  cases  was  reported  among  those  aged  <2  years  (53.1%).  Of all  serious  ESAVI  reported,  37.8%  were
classiﬁed  as  coincidental,  35.3%  as  related  to vaccine  components,  26.4%  as  non-conclusive  and  0.5%  as a
programmatic  error.
This  regional  overview  of  A[H1N1]pdm  vaccine  safety  data  in  LAC  estimated  the  rate of  serious  ESAVI  at
lower levels  than  other  studies.  However,  the  ESAVI  diagnosis  distribution  is  comparable  to the  published
literature.  Lessons  learned  can  be applied  in  the  response  to future  pandemics.. Introduction
In recent years, there has been rapid uptake in seasonal
nﬂuenza vaccination in the Americas; prior to the emergence of
he inﬂuenza A (H1N1) virus, 35 out of 46 countries and territo-
ies had introduced the seasonal vaccine, compared to 13 countries
nd territories in 2004 [1]. Common target populations included
∗ Corresponding author at: Pan American Health Organization, Comprehensive
amily Immunization Unit, Room 507, 525 Twenty Third St., NW,  Washington, DC
0037-2895, USA. Tel.: +1 202 974 3706; fax: +1 202 974 3635.
E-mail address: roperoal@paho.org (A.M. Ropero-Álvarez).
1 Current address: Department of Preventive Medicine and Public Health, Faculty
f  Medicine, National University of San Marcos, Lima, Peru.
ttp://dx.doi.org/10.1016/j.vaccine.2014.10.070
264-410X/© 2014 Published by Elsevier Ltd.© 2014  Published  by  Elsevier  Ltd.
the elderly, children, and individuals with chronic disease [1,2].
As the use of seasonal inﬂuenza vaccine expanded, so too did the
surveillance capacity to monitor Events Supposedly Attributable
to Vaccination or Immunization (ESAVI); this terminology is com-
monly used in Latin America and the Caribbean (LAC) and is deﬁned
as a clinical condition following vaccine administration, which may
or may  not be related to the vaccination and which causes great
concern among the population [3]. In most countries, ESAVI surveil-
lance is passive and based on voluntary and spontaneous reports
from health providers [4].
In June 2009, Dr. Margaret Chan, Director General of the World
Health Organization (WHO), declared that circulation of inﬂuenza
A (H1N1) had reached pandemic levels [5]. From the pandemic’s
onset, there were particular concerns about A[H1N1]pdm vac-
cine safety, despite the proven safety of the seasonal vaccine [6].
1 l. / Vac
C
f
a
o
i
m
p
o
a
t
n
S
p
i
v
t
2
2
l
E
e
P
r
n
n
f
g
t
o
s
o
1
q
p
2
a
a
2
r
o
n
v
s
2
v
m
i
w
a
o
p
the ﬁrst clinical diagnosis reported by the country was selected;
95% conﬁdence intervals (CI) were calculated for all rates. Descrip-
tive analysis was  done on ﬁnal outcomes and classiﬁcations given in88 A.M. Ropero-Álvarez et a
oncerns were centered around the short time frame available
or A[H1N1]pdm vaccine production, manufacturers’ use of novel
djuvants (AS03, MF59), and the antecedent temporal association
f a previous inﬂuenza vaccine with Guillain-Barré Syndrome (GBS)
n the 1970s [7,8].
LAC countries and territories administered approximately 144.6
illion doses of A[H1N1]pdm vaccine in a series of national cam-
aigns, placing LAC as one of the regions with the highest number
f doses administered [9]. Campaign timing was  based on the
vailability of vaccine at the national level, which differed country
o country; however, with the exception of Venezuela, all vacci-
ation campaigns in LAC occurred between December 2009 and
eptember 2010. Venezuela vaccinated and reported after this
eriod. This paper describes serious ESAVI reported in LAC follow-
ng A[H1N1]pdm emergency vaccination to further document the
accine’s safety proﬁle and its implications for national immuniza-
ion programs (NIPs), as well as highlights lessons learned.
. Methods
.1. Preparation for A[H1N1]pdm ESAVI surveillance in LAC
Since 2002, countries in LAC have had at their disposal guide-
ines for ESAVI response [10]; to support country efforts to carry out
SAVI surveillance as part of A[H1N1]pdm vaccination campaigns,
fforts were made to enhance this routine surveillance across LAC.
lanning for A[H1N1]pdm vaccine safety monitoring also incorpo-
ated lessons learned from the Safety of New Vaccines (SANEVA)
etwork, developed in 2006 to monitor adverse events related to
ew vaccines [11].
The Pan American Health Organization, WHO’s Regional Ofﬁce
or the Americas (PAHO/WHO) elaborated and distributed a ﬁeld
uide speciﬁc to A[H1N1]pdm ESAVI surveillance, crisis preven-
ion and management [12]. Several months before the arrival
f vaccine, a workshop was held for ofﬁcers in charge of ESAVI
urveillance from the NIP, professionals from national epidemiol-
gy departments and national regulatory authorities representing
6 LAC countries. This workshop promoted collaboration and fre-
uent communication between all relevant actors and emphasized
rompt ESAVI reporting, investigation, and ﬁnal classiﬁcation.
.2. Surveillance period
PAHO asked its Member States to report A[H1N1]pdm ESAVI on
 weekly basis, beginning at the start of their vaccination campaign
nd continuing on until 45 days following its ﬁnalization.
.3. Surveillance instrument
Countries used a standardized format for A[H1N1]pdm ESAVI
eporting, which included variables of age, gender, place and date
f vaccination, date of symptom onset, timeframe between vacci-
ation and symptom onset, concomitant administration of other
accines, whether the vaccine contained adjuvant, clinical diagno-
is, clinical outcome, and ESAVI classiﬁcation.
.4. Target populations for vaccination
Due to the initially limited quantities of available A[H1N1]pdm
accine, in 2009, PAHO’s Technical Advisory Group (TAG) recom-
ended the prioritization of target populations for vaccination,
ncluding health care workers, pregnant women and individuals
ith chronic illness older than 6 months of age. Depending on
 country’s epidemiological situation, resources and the capacity
f the NIP, the TAG recommended expanding vaccination to other
opulation risk groups, including children aged 6 months to 4 years,cine 33 (2015) 187–192
healthy school-aged children and adults aged 19–49 years [13]. The
ﬁnal deﬁnition of target groups and goals were at the discretion of
each country.
2.5. Events under surveillance
PAHO’s A[H1N1]pdm ESAVI ﬁeld guide focused on ESAVI sig-
nal detection, clusters, serious or fatal events, and rumors. Even
though all ESAVI were to be reported, emphasis was given to febrile
seizures, anaphylaxis, GBS and outcomes among pregnant women.
Countries were encouraged to use the case deﬁnitions developed
internationally under the Brighton Collaboration [14] in order to
standardize reporting and ﬁnal classiﬁcation [15].1
2.6. Case deﬁnition
An ESAVI was considered serious if it resulted in death, hospi-
talization or prolongation of existing hospitalization, persistent or
signiﬁcant disability or incapacity, or if it was  considered a life-
threatening event. Only cases reported as serious ESAVI by the
countries are included in this analysis. Serious ESAVI were fur-
ther classiﬁed at the country level following the ﬁnal classiﬁcations
developed by PAHO/WHO, which included whether the ESAVI was
considered related to the vaccine, related to a programmatic error,
a coincidental event or inconclusive [3,10].
2.7. Causality assessment and ﬁnal classiﬁcation
Causality assessment and ﬁnal classiﬁcation was  generally
tasked to the Ministries of Health in the region; however, depend-
ing on the complexity of each case, countries convened National
ESAVI Committees to guide the investigation and to provide ﬁnal
classiﬁcation. The assessment of ﬁnal ESAVI outcomes, regard-
less of ﬁnal classiﬁcation, was also done in country and based on
WHO deﬁnitions, which included whether an ESAVI was recov-
ered/resolved, recovering/resolving, not recovered/not resolved,
recovered/resolved with sequelae, fatal, or whether the ﬁnal out-
come was unknown [16].
PAHO established an ongoing dialogue with national author-
ities in charge of ESAVI surveillance to discuss and clarify any
concerns raised during case revision; particular focus was  again
given to febrile seizures, anaphylaxis, GBS and ESAVI during preg-
nancy. PAHO only reviewed the reported data but was  not in a
position to discard any serious A[H1N1]pdm ESAVI cases reported
by countries. As mentioned before, this article includes all serious
A[H1N1]pdm ESAVI reported by LAC countries; data was  updated
for the last time in May  2012, when a ﬁnal revision of country infor-
mation was completed during a regional vaccine safety meeting.
2.8. Statistical analysis
All data collected were consolidated into Excel and the fre-
quency of serious ESAVI by age, sex and target group was calculated.
Information on A[H1N1]pdm vaccine doses administered to preg-
nant women, health care workers and people with chronic health
conditions was  also obtained from countries, in order to calculate
reported rates of serious ESAVI per million doses in these groups.
Given that an individual patient could present more than one ESAVI,1 The Brighton Collaboration is an international, independent network which pro-
vides standardized methods to monitor vaccine safety.
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ountry. Microsoft Excel 2010® and SPSS software package (version
0) were used for analysis.
. Results
In LAC, 1000 serious ESAVI were reported by 18 of the 29
ountries and territories that implemented vaccination campaigns
gainst A[H1N1]pdm. Additionally, Cuba reported 8 serious ESAVI,
ut as individual case information was not available, they were not
onsidered in this analysis; however, additional information has
een reported elsewhere [17]. The remaining 10 countries and ter-
itories reported only non-serious ESAVI [18]. Country reporting
ates ranged from 0.77 to 64.68 serious ESAVI per million doses.
he overall reporting rate in LAC was 6.91 serious ESAVI cases per
illion doses (Table 1).
By age group (n = 984), the largest percentage of serious ESAVI
ere reported in children less than 18 years of age (49.8%); within
his group, the highest number of serious ESAVI was  concentrated
n children less than 2 years of age (53.1%). Adults aged 18–59 years
epresented 43.2% of serious ESAVI reported in LAC, followed by
ndividuals aged 60 years or older (7.0%) (Table 2).
Vaccination by sex was not available in order to calculate rates;
owever, serious ESAVI were reported more frequently among
ales (57.8%) (n = 851). Data were only available to calculate the
ate of serious ESAVI among the population target groups of preg-
ant women (16.25 cases per million doses), health care workers
13.54 cases per million doses) and people with chronic health
onditions (4.03 cases per million doses) (Table 2).
Rates of serious ESAVI by vaccine manufacturer could not be
alculated due to the absence of data on doses administered disag-
regated by producer. Out of the total number of serious ESAVI
eported with information available on the presence of adju-
ant (n = 877), 57.8% of cases had received unadjuvanted vaccine
Table 2). Through PAHO’s Revolving Fund for Vaccine Procurement
nd WHO  vaccine donations, approximately 20.2 million doses of
nadjuvanted vaccine and 10.4 million doses of adjuvanted vaccine
oses were received in LAC. An additional 151 million doses were
rocured directly from the manufacturer by Argentina, Brazil, and
exico and information is not available regarding what percentage
f these vaccines contained adjuvant [18].
Among the serious ESAVI reported in LAC, the most frequently
eported diagnoses were febrile seizures (12.0%), GBS (10.5%), acute
neumonia (8.0%), anaphylaxis (7.6%), seizures (6.1%) and hypo-
onic hyporesponsive episodes (HHE) (5.6%), which accounted for
lmost half of all cases. All reporting rates were under 1 case per
illion doses (Table 3).
Among the 260 serious ESAVI reports in children less than 2
ears of age, the most frequent diagnoses were febrile seizures
34.6%), HHE (14.2%), acute pneumonia (10.3%), non-febrile
eizures (8.1%) and anaphylaxis (5.4%); the same sequential order
f diagnoses was observed for all children less than 18 years of age
Table 3). Within this group, the majority of ESAVI cases occurred
mong males (52.6%). Seventy-four children less than 2 years of
ge received concomitant vaccination along with A[H1N1]pdm
accine; it was not possible to differentiate which vaccine was
esponsible for the ESAVI. Information on concomitant vaccination
or the most frequently reported ESAVI is shown in Table 4.
Among the 425 serious ESAVI reports in adults aged 18–59 years,
BS (12.5%), anaphylaxis (10.6%), miscarriage (9.4%) acute pneu-
onia (6.1%), Bell’s palsy (5.9%) and seizures (4.0%) were the most
ommon diagnoses, both for healthy individuals and those with
hronic conditions (Table 3). The majority of cases (72.2%) were
emale.
Among older adults (n = 69), the most common clinical diag-
oses were GBS (26.1%), acute pneumonia (14.5%), anaphylaxiscine 33 (2015) 187–192 189
(8.7%), polyneuropathy (7.2%), Bell’s palsy (5.8%) and sudden death
(4.3%) (Table 3). In this group, 58.2% (32/55) of cases were male.
3.1. Monitoring of speciﬁc A[H1N1]pdm ESAVI diagnosis
Febrile seizures were only reported among children, with a
median age of 16 months (range from 6 months to 12 years). Time of
onset was available for 97.5% (n = 117) of cases, with a median of 9 h
after vaccination (interquartile range [IQR]: 9–24 h). A total of 116
(99.1%) cases occurred within 72 h after vaccination: 97 (80.8%) in
the ﬁrst 24 h, 6 (5.0%) between 24 and 48 h and 3 (2.5%) between 48
and 72 h. Febrile seizures were more frequent among males (55.7%).
The largest proportion of GBS cases was reported in adults
(67.6%), with a median age of 29.9 years (range from 9 months–79.2
years). Date of onset was available for 92.4% (n = 97) of cases, with a
median time of 12 days after vaccination (IQR: 5 days- 26 days). Out
of the 97 cases, a total of 89 cases (91.8%) occurred within 42 days
after vaccination. No cases were reported among pregnant women.
Cases were distributed evenly between males and females.
The median age of anaphylaxis cases (n = 76) was 30 years (range
from 6 months to 70 years). Time of onset was available for 92.1%
(n = 70) of cases, with a median time of 60 min  after vaccination
(IQR: 60–495 min); 41 of these cases (53.9%) cases occurred in the
ﬁrst hour and 24 (31.6%) cases occurred between the ﬁrst hour
but within 24 h after vaccination. Anaphylaxis was  more common
among women (75.4%).
Among pregnant women  (n = 78), the most frequent clinical
diagnoses were miscarriage (57.7%), and preterm labor and deliv-
ery (6.4%). A total of 4801,168 doses were administered to pregnant
women with an overall rate of reported events of 16.25 (95% CI:
12.64–19.43) cases per million doses.
3.2. A[H1N1]pdm ESAVI ﬁnal outcomes and classiﬁcation
Most reported serious ESAVI cases had a positive clinical out-
come. Of the 898 serious ESAVI cases with available information on
ﬁnal outcome, 65.9% fully recovered, 21.0% recovered with seque-
lae (miscarriages were included here), 8.0% died and 5.0% were still
hospitalized at the time of the ﬁnal revision of country data with
no additional information provided. Countries reported 72 deaths
following vaccination among the approximately 144.6 million indi-
viduals vaccinated. The median age at death was 27.3 years (range
from 6 months to 92 years). Main causes of death were reported as
sudden death (33.4%), acute pneumonia (18.1%), myocardial infarc-
tion (5.6%), cerebrovascular accident (4.2%) and bronchoaspiration
(4.2%). Most fatalities were among healthy adults >60 years (29.2%),
followed by people with chronic illnesses (17.1%), adults (9.0%),
health care workers (5.6%), pregnant women (5.3%) and children
(4.3%). Of all serious ESAVI reported in LAC, 37.8% were ultimately
classiﬁed by countries as coincidental events (2.61 per million
doses), 35.3% as related to vaccine components (2.44 per million
doses) and 0.5% as programmatic errors (0.03 per million doses).
The remaining 26.4% of cases were classiﬁed as non-conclusive.
4. Discussion
This article represents the ﬁrst overview of A[H1N1]pdm vac-
cine safety data in LAC following widespread vaccination in 2010
and replaces preliminary information reported previously [18].
Across the region, ESAVI surveillance systems were able to detect
safety signals following A[H1N1]pdm vaccination. While reported
rates of serious ESAVI varied greatly by country, they were consis-
tent with the literature and contributed to a better understanding
the vaccine’s safety proﬁle [19–24].
Countries’ ability to conduct causality assessments varied sub-
stantially and data limitations at the regional level restricted
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Table  1
Serious ESAVI reported by LAC countries and territories.
Countrya Number of doses
administered
Reported number of
serious ESAVI
Rate per million doses 95% C.I.
Brazil 92,000,000 612 6.65 6.12–7.18
Mexico  26,903,232 154 5.72 4.82–6.63
Argentina 8,258,009 109 13.20 10.72–15.68
Chile  3,084,124 28 9.08 5.72–12.44
Ecuador  973,480 20 20.54 11.54–29.55
Colombia 2,037,301 16 7.85 4.01–11.70
Honduras 1,810,783 12 6.63 2.88–10.38
Paraguay 1,087,661 12 11.03 4.79–17.28
Peru  2,237,053 10 4.47 1.70–7.24
Bolivia  1,249,049 5 4.00 0.49–7.51
Uruguay 538,057 5 9.29 1.15–17.44
Venezuela 500,000 4 8.00 0.16–15.84
Costa Rica 180,000 3 16.67 0.00–35.53
Nicaragua 251,759 3 11.92 0.00–25.40
Suriname 24,674 3 64.68 0.00–137.86
Panama 254,286 2 7.87 0.00–18.77
Cayman Islandsb 2,318 1 – –
Guatemala 1,295,742 1 0.77 0.00–2.28
Other countriesc 1,934,065 0 – –
Total  144,621,593 1000 6.91 6.49–7.34
a Cuba did not report individual case information for reported serious ESAVI, and therefore, it was not included in the analysis. In the country, a total of 1123,526 doses
were  administered and 3401 ESAVI cases were reported, 8 of which were classiﬁed as serious.
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c Includes doses administered in Bahamas, Barbados, Belize, Bermuda, El Salva
ountries and territories that did not report serious ESAVI cases.
alculating rates among certain target groups and other in-depth
nalyses. Despite such limitations, lessons learned have helped
o strengthen current ESAVI surveillance systems in LAC, bet-
er preparing them to respond to future pandemics and other
mmunization-related emergencies.
The rate of serious ESAVI reported in LAC (6.91 per million doses)
as signiﬁcantly lower than the rate reported in Europe (38.2 per
illion doses) and slightly lower than in the United States (8.8 per
illion doses) and China (7.9 per million doses), where ESAVI noti-
cation was also through passive surveillance systems [19–21].
evertheless, the doses administered in LAC were almost three
imes higher than in Europe, the United States and China. The lower
egional rate may  be explained by either the lower occurrence of
ases or, more likely, by the nature of the reporting systems in
AC, which may  have allowed for more under-reporting, biased
able 2
eported serious ESAVI following A[H1N1]pdm vaccination by demographic characterist
Characteristic Reported number of serious ESAVI % 
Age (years) n = 984
≤2 260 26.4 
2–4  110 11.1 
5–17  120 12.2 
18–59 425 43.2 
≥60 69 7.0
Sex  n = 851
Female 359 42.2 
Male 492 57.8 
Vaccination group n = 997
Children < 18 yearsa 434 43.4 
Adultsb 243 24.3 
Chronic health conditionsc 138 13.8 
Health care workers 78 7.9 
Pregnant womend 78 7.8 
Adults ≥60 y 26 2.6 
Type of vaccine n = 877
Adjuvanted 370 42.2 
Non  adjuvanted 507 57.8 
a Does not include children with chronic health conditions or pregnant women.
b Healthy adults (18–59 years old); does not include chronic health conditions, health 
c Includes people of all ages.
d May  include pregnant women <18 years of age.renada, Guyana, Montserrat, Trinidad and Tobago, and Turks and Caicos Islands,
reporting (in relation to severity, and timing of adverse events) and
inconsistency in the quality and completeness of reports.
The reported rate of serious ESAVI varied greatly between coun-
tries but is consistent with the A[H1N1]pdm literature and with
what has been observed in seasonal inﬂuenza campaigns [19–24].
Data variability by country is also likely due to the heterogeneous
capacity of the national surveillance systems to detect ESAVI and
fully investigate them [25].
Across LAC, the rate of GBS (0.73 cases per million doses across
all ages, 95%CI: 0.59–0.86) fell within what has been published in
similar studies worldwide (0.8 to 1.9 cases per million vaccinations)
[19,20,23], while the rate of anaphylaxis (0.53 cases per million
doses across all ages) was  lower than that reported from Europe and
the United States, [19,20,23] and similar to that reported from China
[21]. Misdiagnosis may  have occurred, for example onset of GBS
ics and vaccine type, LAC.
Number of doses Reported rate per million doses 95%CI
– –
– –
– –
– –
– –
– –
– –
– –
33,492,168 4.03 3.35–4.65
5,833,641 13.54 10.56–16.18
4,801,168 16.25 12.64–19.43
– –
– –
– –
care workers, pregnant women  or adults 60 years old or over.
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Table  3
Clinical diagnosis of serious ESAVI following A[H1N1]pdm vaccination by age groupa, LAC.
Clinical Diagnosis Reported number
of serious ESAVI
% Rate per
million doses
95% CI ≤2 years 2–4 years 5–17 years 18–59 years ≥60 years
Febrile seizures 120 12.0 0.83b 0.68–0.98 90 25 5 – –
Guillain-Barré syndrome 105 10.5 0.73 0.59–0.86 4 11 16 53 18
Acute Pneumonia 80 8.0 0.55 0.43–0.67 27 8 9 26 10
Anaphylaxis 76 7.6 0.53 0.41–0.64 14 1 6 45 6
Seizures 61 6.1 0.42 0.32–0.53 21 9 13 17 1
Hypotonic–hyporesponsive episode 56 5.6 0.39b 0.29–0.49 37 10 9 – –
Miscarriage 45 4.5 0.31 0.22–0.40 – – 5 40 –
Encephalitis, myelitis,
encephalomyelitis and
encephalopathy
35 3.5 0.24 0.16–0.32 7 1 7 14 3
Bell’s palsy 31 3.1 0.21 0.14–0.29 1 – 1 25 4
Sudden deathc 26 2.6 0.18 0.11–0.25 4 3 3 13 3
Syncope 22 2.2 0.15 0.09–0.22 1 3 3 14 1
Polyneuropathy 22 2.2 0.15 0.09–0.22 5 1 5 6 5
Paralytic syndromed 19 1.9 0.13 0.07–0.19 3 2 2 11 1
Ataxia 13 1.3 0.09 0.04–0.14 3 6 4 – –
Thrombocytopenic purpura 13 1.3 0.09 0.04–0.14 3 5 3 2 –
Other 276 27.6 1.91 1.68–2.13 40 25 29 159 17
Total  1000 100.0 6.91 6.49–7.34 260 110 120 425 69
a Data on age group was  not available for 16 cases of serious ESAVI.
b Rates per million doses were calculated using the total number of doses applied across all age groups, as the total number of doses applied in certain age and risk groups
was  not available.
c Includes two infant deaths.
d Includes the diagnosis of Paralytic Syndrome, paresis, monoplegia and hemiplegia.
Table 4
Serious ESAVI following A[H1N1]pdm in children less than 2 years of age and number and percentage of children who received concomitant vaccination.
Clinical diagnosis Reported number
of  serious ESAVI
Number of children who received
concomitant vaccination (%)
Other vaccines administered
Febrile seizures 90 27 (30.0) 4 DPT-Penta; 17 PCV; 4 OPV; 2 HepB; 1 MMR
Hypotonic–hyporesponsive episode 37 10 (27.0) 7 DPT-Penta; 6 OPV; 3 PCV; 1 rotavirus
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wAcute  pneumonia 27 4 (14.8) 
Non  febrile seizures 21 6 (28.6) 
Anaphylaxis 14 5 (35.7) 
ay  have been to soon to be plausible and some cases diagnosed
s anaphylaxis occurred more than 24 h following vaccination.
Among serious ESAVI reported in pregnant women, more than
alf involved miscarriage (57.5%). Our data did not suggest any
afety signals in this group. These ﬁndings were similar to those
n other countries including the United States [26]. Internationally,
ata from A[H1N1]pdm vaccine surveillance did not identify safety
oncerns among either pregnant women or their infants [26–30].
Given the nature of passive reporting systems, national
[H1N1]pdm ESAVI surveillance systems generally could not pro-
ide evidence of a causal association between vaccination and
eported serious ESAVI. Despite regional efforts to standardize this
rocess, including fostering active participation and technical guid-
nce on the part of National ESAVI Committees, countries’ ability
o assess causality varied substantially. Data reported in this article
s based on countries’ classiﬁcations of their own cases; additional
nformation, such as medical ﬁles and death certiﬁcates, to con-
rm classiﬁcations, was  not available to PAHO. It is also likely
hat the Brighton Collaboration case deﬁnitions were used incon-
istently country to country. While countries were requested to
eport data on a weekly basis, information was often reported less
requently. Additional data limitations include the lack of reliable
enominators for all targeted age/risk groups, or by type of vac-
ine (adjuvanted or not), which limited the calculation of ESAVI
ncidence rates.
The experience of LAC during the response to the A[H1N1] pan-
emic provide valuable lessons learned in strengthening current
SAVI surveillance systems. First, the cornerstone of effective mon-
toring of vaccine safety is the development of close collaboration
ithin a country between NIPs, epidemiology departments and2 Seasonal inﬂuenzal; 2 PCV; 1 meningococcal C
3 OPV; 3 Penta; 3 PCV
3 PCV-10; 2 DPT-Penta
regulatory bodies. Adequate staff training must take place before a
vaccine is used, with emphasis on data collection and analysis. Sec-
ond, countries should prioritize collecting baseline data regarding
speciﬁc health outcomes, to be able to better document a vac-
cine’s safety proﬁle. Third, core reporting ESAVI variables should
be disseminated to countries, including the periodicity of report-
ing to the regional level, to ensure collecting harmonized safety
data, and thus, enabling a better comparison and pooled analysis
at the regional and global level. Additionally, there is still a need to
continue strengthening and standardizing the process of causality
assessment by national safety committees.
Finally, countries should work to address speciﬁc limitations of
their ESAVI surveillance systems, as identiﬁed during the A[H1N1]
pandemic, in order to improve future pandemic response, as well
as ESAVI surveillance in general.
Given their important limitations (underreporting, biased
reporting, differential reporting, etc), passive surveillance systems
are not designed to conﬁrm associations between vaccines and
ESAVI, their main role is to generate safety signals deserving further
investigation in analytical studies. To properly investigate safety
signals, well designed active surveillance systems and observa-
tional studies are needed. For this reason, PAHO is working toward
the development of a hospital-based active ESAVI surveillance
system, to allow epidemiologically valid veriﬁcation of suspected
associations, even when events are rare [31].Acknowledgements
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